Search research articles
Contact Us
Filters
Showing results (11-20 of 174) with videos related to
Page
of 18
Sort By:
The Oncologist
|
October 10, 2015
Susan Bates, M.D., and Antonio "Tito" Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute
Sham Mailankody, Vinayak Prasad
JAMA Oncology
|
November 24, 2017
Overall Survival vs Disease-Specific Survival-Reply
Sham Mailankody, Vinay Prasad
JAMA Oncology
|
November 29, 2016
Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World
Sham Mailankody, Vinay Prasad
Best Practice & Research. Clinical Haematology
|
November 10, 2016
Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia
Sham Mailankody, Ola Landgren
The New England Journal of Medicine
|
August 10, 2022
T-Cell Engagers - Modern Immune-Based Therapies for Multiple Myeloma
Sham Mailankody, Ola Landgren
Seminars in Oncology
|
February 6, 2022
"Off-the-shelf" immunotherapies for multiple myeloma
Turab Mohammed, Sham Mailankody
JAMA
|
January 23, 2014
The accelerated approval of oncologic drugs: lessons from ponatinib
Vinay Prasad, Sham Mailankody
JAMA Oncology
|
September 11, 2015
Pricing and Value of Cancer Drugs--Reply
Sham Mailankody, Vinay Prasad
JAMA Internal Medicine
|
April 4, 2018
Assessing Pharmaceutical Research and Development Costs-Reply
Vinay Prasad, Sham Mailankody
BMJ (Clinical Research Ed.)
|
September 22, 2020
Emerging immunotherapies in multiple myeloma
Urvi A Shah, Sham Mailankody
Page
of 18
Search research articles
Search
Showing results (11-20 of 174) with videos related to
Sort By:
Page
of 18
The Oncologist
|
October 10, 2015
Susan Bates, M.D., and Antonio "Tito" Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute
Sham Mailankody, Vinayak Prasad
JAMA Oncology
|
November 24, 2017
Overall Survival vs Disease-Specific Survival-Reply
Sham Mailankody, Vinay Prasad
JAMA Oncology
|
November 29, 2016
Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World
Sham Mailankody, Vinay Prasad
Best Practice & Research. Clinical Haematology
|
November 10, 2016
Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia
Sham Mailankody, Ola Landgren
The New England Journal of Medicine
|
August 10, 2022
T-Cell Engagers - Modern Immune-Based Therapies for Multiple Myeloma
Sham Mailankody, Ola Landgren
Seminars in Oncology
|
February 6, 2022
"Off-the-shelf" immunotherapies for multiple myeloma
Turab Mohammed, Sham Mailankody
JAMA
|
January 23, 2014
The accelerated approval of oncologic drugs: lessons from ponatinib
Vinay Prasad, Sham Mailankody
JAMA Oncology
|
September 11, 2015
Pricing and Value of Cancer Drugs--Reply
Sham Mailankody, Vinay Prasad
JAMA Internal Medicine
|
April 4, 2018
Assessing Pharmaceutical Research and Development Costs-Reply
Vinay Prasad, Sham Mailankody
BMJ (Clinical Research Ed.)
|
September 22, 2020
Emerging immunotherapies in multiple myeloma
Urvi A Shah, Sham Mailankody
Page
of 18